Genetic variations associated with cisplatin-induced ototoxicity identified
the ONA take:
The anti-cancer drug cisplatin is widely administered to treat brain cancer and other tumors, but some individuals treated with cisplatin experience severe hearing loss, among other side effects.
But the effect of patients varies widely. The reasons why some patients were affected has not been fully understood, but a group of investigators based at St. Jude Children's Research Hospital feel the cause of rooted in genetic variations.
The research team examined DNA from 238 patients with brain tumors and took into account some 1.7 million common genetic variations, looking for a link to the cisplatin-related hearing loss. This was the first time a possible genetic cause of this side effect had been investigated.
The result: genetic variations in a gene called ACYP2 were linked to as much as a four-fold increase of risk for hearing loss. This association was verified in a separate group of 68 patients after other risk factors, such as radiation treatment or age, were eliminated. Individuals with at least one copy of the ACYP2 variant experienced hearing loss, establishing a link to that genetic variation, but additional individuals also experienced hearing loss so the researchers feel other, not-yet-identified genetic variations are also at play.
This research could be the first step in identified patients receiving cisplatin that are at high risk of hearing loss. Additional research into why the ACYP2 variations actually trigger the hearing is needed.
The anti-cancer drug cisplatin is widely administered to treat brain cancer and other tumors.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|